Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer

Abstract

The recommended dose for phase II studies is 125 mg/m2 oxaliplatin.

Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer

“…30,40 Furthermore, chronotherapy theoretically should be more toxic to tumor cells because of poor circadian rhythm and greater cell cycle variability in malignant tissues compared with healthy tissues. 49 Although it has been demonstrated that HAI with irinotecan or oxaliplatin is not complicated by cholangitis, [20][21][22][23][24][25][26][27][28][29] it can be anticipated in as many as 30% of patients who receive HAI floxuridine. [46][47][48] This HAI chronotherapy regimen is well tolerated with no chemical bile duct sclerosis, whereas chronotherapy is not expected to decrease bile excretion of 5-FU metabolites.…”

“…Oxaliplatin HAI reportedly was feasible, and its combination with iv 5-FU-LV achieved a high response rate in pretreated patients. [24][25][26][27][28][29] Both the terminal half-life of and the systemic exposure to free plasma platinum were decreased by HAI of oxaliplatin, a finding that supports its lower systemic toxicity compared with iv administration. 27 Such liver-directed chemotherapy could benefit further from adjustment of the drug-delivery pattern to the circadian clock in healthy hepatocytes.…”

“…[24][25][26][27][28][29] Both the terminal half-life of and the systemic exposure to free plasma platinum were decreased by HAI of oxaliplatin, a finding that supports its lower systemic toxicity compared with iv administration. 27 Such liver-directed chemotherapy could benefit further from adjustment of the drug-delivery pattern to the circadian clock in healthy hepatocytes. 30 Normal mammalian cells contain a molecular clock that regulates the cell cycle, apoptosis, gene expression, and DNA repair.…”

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity

“…Different agents have been used to treat hepatic metastasis from various tumor types: cisplatin (6-9), oxaliplatin (10)(11)(12)(13)(14), paclitaxel (15,16), floxuridine (FUDR; refs. (17)(18)(19)(20)(21), interleukin-2 (22, 23), 5-fluorouracil/leucovorin (24), and IFN (25)(26)(27)(28).…”

Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection

“…It is also associated with an acute neuropathy mild which reverses in several hours or days [6,7]. Oxaliplatin can also produce diarrhea, vomiting, and hematological suppression [7][8][9]. However, the mechanisms of action and toxicity are not clear.…”